[go: up one dir, main page]

IL86650A0 - Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane - Google Patents

Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane

Info

Publication number
IL86650A0
IL86650A0 IL86650A IL8665088A IL86650A0 IL 86650 A0 IL86650 A0 IL 86650A0 IL 86650 A IL86650 A IL 86650A IL 8665088 A IL8665088 A IL 8665088A IL 86650 A0 IL86650 A0 IL 86650A0
Authority
IL
Israel
Prior art keywords
cells
liposomes
animal derived
membrane
derived cells
Prior art date
Application number
IL86650A
Other languages
English (en)
Original Assignee
Biophor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26748809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL86650(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biophor Corp filed Critical Biophor Corp
Priority to IL10569288A priority Critical patent/IL105692A/en
Publication of IL86650A0 publication Critical patent/IL86650A0/xx
Priority to IL105692A priority patent/IL105692A0/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G01N33/555—Red blood cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
IL86650A 1987-06-30 1988-06-07 Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane IL86650A0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL10569288A IL105692A (en) 1987-06-30 1988-06-07 Liposomes to which a membrane has been inserted angiotic protein
IL105692A IL105692A0 (en) 1987-06-30 1993-05-13 Liposomes having an antigenic protein incorporated into their membranes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6828887A 1987-06-30 1987-06-30
US19744588A 1988-05-27 1988-05-27

Publications (1)

Publication Number Publication Date
IL86650A0 true IL86650A0 (en) 1988-11-30

Family

ID=26748809

Family Applications (1)

Application Number Title Priority Date Filing Date
IL86650A IL86650A0 (en) 1987-06-30 1988-06-07 Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane

Country Status (9)

Country Link
US (1) US5677176A (xx)
EP (1) EP0298280B1 (xx)
JP (2) JP2728166B2 (xx)
AT (1) ATE114476T1 (xx)
AU (2) AU1821988A (xx)
CA (1) CA1327332C (xx)
DE (1) DE3852221T2 (xx)
ES (1) ES2067457T3 (xx)
IL (1) IL86650A0 (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310654A (en) * 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes
CA1327174C (en) * 1988-10-05 1994-02-22 Youssef Mouneimne Electro-insertion of proteins into animal cell membranes
JPH04502168A (ja) * 1988-12-22 1992-04-16 ザ　ダウ　ケミカル　カンパニー 複素環式ポリマーの改良合成方法
US5753258A (en) * 1990-10-19 1998-05-19 University Of Florida Artificial viral envelopes
US5252348A (en) * 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
EP0555333B1 (en) * 1990-10-19 1995-12-27 University Of Florida Artificial viral envelopes
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
ATE157879T1 (de) * 1991-06-14 1997-09-15 Europ Communities Transformierte erythrozyten, verfahren zu deren herstellung, und ihre verwendung in pharmazeutischen zusammensetzungen
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
EP0630407B1 (en) * 1992-03-11 2000-08-02 PRENDERGAST, Kenneth, Francis Anti-viral fusion peptides
WO1994004677A1 (en) * 1992-08-13 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of cd4 plasma membrane vesicles (pmv) as a therapeutic agent for aids
CA2144767A1 (en) * 1992-09-22 1994-03-31 Guerard W. Byrne Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes
US5840328A (en) * 1994-01-11 1998-11-24 The Liposome Company, Inc. Treatment using arachidonic acid metabolite and particulate formulations
DE69508255T2 (de) * 1994-07-15 1999-10-14 Biosearch Italia S.P.A. Dinukleosid-5',5'- pyrophosphate
US5591448A (en) * 1994-11-21 1997-01-07 Tepic; Slobodan Anti-viral therapeutic composition
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
AU1734600A (en) * 1998-11-17 2000-06-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Identification of glycosphingolipids that promote hiv-1 entry into cells
KR100638150B1 (ko) 1998-12-23 2006-10-26 이데아 악티엔게젤샤프트 생체내에서 국부적인 비침습성 용도로 사용되는 개선된 제제
ATE216223T1 (de) 1999-01-27 2002-05-15 Idea Ag Transnasaler transport bzw. impfung mit hochadaptierbaren trägern
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
EP1921451A3 (en) * 2001-05-22 2008-05-28 Cygene, Inc. Complement mediated assays for in vivo and in vitro methods
DE60233885D1 (de) 2001-10-16 2009-11-12 Kode Biotech Ltd Aus modifizierten zellen präparierte empfindlichkeitskontrollen für blutserologie
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US20050032113A1 (en) * 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
CN102046151A (zh) * 2008-03-26 2011-05-04 牛津大学 靶向内质网的脂质体
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20110092961A1 (en) * 2008-08-13 2011-04-21 Searete Llc Artificial cells
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US8926543B2 (en) 2009-10-08 2015-01-06 Otsuka Pharmaceutical Co., Ltd. Immunoactivation blood perfusion filter for the treatment of malignant tumors
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
CA2944492A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA806506B (en) * 1979-11-01 1981-09-30 Bio Response Inc A method for production of monoclonal antibodies
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
FR2564319A1 (fr) * 1984-05-21 1985-11-22 Inst Nat Sante Rech Med Nouvelles compositions de liposomes dotees d'une action specifique vis-a-vis de la proliferation de cellules donnees
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes

Also Published As

Publication number Publication date
AU662154B2 (en) 1995-08-24
DE3852221D1 (de) 1995-01-12
JP2728166B2 (ja) 1998-03-18
JP2825804B2 (ja) 1998-11-18
JPH01124382A (ja) 1989-05-17
EP0298280A3 (en) 1990-05-02
ATE114476T1 (de) 1994-12-15
AU1821988A (en) 1989-04-27
EP0298280A2 (en) 1989-01-11
DE3852221T2 (de) 1995-04-06
EP0298280B1 (en) 1994-11-30
CA1327332C (en) 1994-03-01
US5677176A (en) 1997-10-14
ES2067457T3 (es) 1995-04-01
AU1942692A (en) 1992-09-24
JPH1072368A (ja) 1998-03-17

Similar Documents

Publication Publication Date Title
IL86650A0 (en) Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
Zaremba et al. Assembly polypeptides from coated vesicles mediate reassembly of unique clathrin coats.
Schwartz et al. Impairment of T cell receptor-dependent stimulation in CD4+ lymphocytes after contact with membrane-bound HIV-1 envelope glycoprotein
Masucci et al. Effect of interferon-α1 from E. coli on some cell functions
ES8503951A1 (es) Un procedimiento para preparar un complejo inmunogenico que contiene proteinas o peptidos antigenicos
EP0158277A3 (de) Implantierbare Zubereitungen von regulatorischen Peptiden mit gesteuerter Freisetzung und Verfahren zur ihrer Herstellung
DE69033700D1 (de) Il-11 aus säugetier
ES2099066T3 (es) Antigenos a partir de adn sintetico derivado del virus de la inmunodeficiencia humana (hiv-1).
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
NO912825L (no) Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper.
EP0306219A3 (en) Novel hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids
IT1254360B (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
GR3007031T3 (xx)
Hale et al. Antigen-liposome modification of target cells as a method to alter their susceptibility to lysis by cytotoxic T lymphocytes.
Cerny et al. CD4+ T cells in murine acquired immunodeficiency syndrome: evidence for an intrinsic defect in the proliferative response to soluble antigen
Gee et al. Differences between Syrian hamster strains in natural killer cell activity induced by infection with Pichinde virus
Bhardwaj et al. The processing and presentation of mycobacterial antigens by human monocytes
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
ES8303522A1 (es) Procedimiento para la mutacion doble de virus del genero herpes
IL86675A (en) Immunogen containing non- infectious hiv particles and pharmaceutical compositions containing the same
Thiel et al. Studies of simian sarcoma and simian sarcoma-associated virus II. Isolation of the major viral glycoprotein, properties of this component and its specific antiserum
ES2061731T3 (es) Procedimiento de extraccion de antigenos de membrana con propiedades inmunogenicas de celulas neoplasicas humanas y los productos asi obtenidos.
Dieleman et al. Acquired Zwa antigen on Zwa negative platelets demonstrated by western blotting
Marušić et al. Involvement of Mhc loci in immune responses that are not Ir-gene-controlled
ES2011679A6 (es) Procedimiento para la preparacion de polipeptidos sinteticos secuenc iales inmunologicamente activos.

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees